BOSTON, July 27, 2026
Bambusa Therapeutics announced encouraging preliminary proof-of-concept results from its ongoing global Phase 1 clinical trial evaluating BBT001, a half-life-extended bispecific antibody targeting IL-4Rα and IL-31, in patients with moderate-to-severe atopic dermatitis (AD). The investigational therapy demonstrated highly statistically significant improvements in eczema severity, rapid itch relief beginning on Day 1, durable suppression of Type 2 inflammatory biomarkers, and a favorable safety profile, reinforcing its potential as a best-in-disease therapy. The findings also support the possibility of maintenance dosing as infrequently as once every three months, with additional clinical data expected during the first half of 2027.
BBT001 Delivers Rapid and Durable Clinical Improvement
The randomized, double-blind, placebo-controlled study enrolled 17 biologic-naïve patients with moderate-to-severe atopic dermatitis, with 12 patients receiving BBT001 and five receiving placebo. BBT001 produced statistically significant placebo-adjusted reductions in the Eczema Area and Severity Index (EASI) beginning as early as Week 1, with clinical responses continuing to improve through Week 6. The investigational therapy achieved placebo-adjusted EASI reductions of 35.6% at Week 1, 61.1% at Week 2, 63.5% at Week 4, and 79.0% at Week 6, all supported by highly significant statistical outcomes. Patients also experienced rapid and progressively greater itch relief beginning on the first day after treatment, while higher proportions achieved EASI-50 and EASI-75 clinical response milestones, highlighting meaningful improvements in skin inflammation and disease severity.
Favorable Safety and Biomarker Findings Strengthen Best-in-Disease Potential
Beyond clinical efficacy, BBT001 demonstrated durable suppression of key Type 2 inflammatory biomarkers, including thymus and activation-regulated chemokine (TARC) and immunoglobulin E (IgE), with reductions sustained for up to eight weeks after the final dose. The therapy was well tolerated, with no cases of conjunctivitis, low immunogenicity, and an extended half-life that supports infrequent maintenance dosing. Investigators also reported low levels of treatment-emergent anti-drug antibodies, with no evidence of neutralizing activity. These findings suggest that BBT001 could offer a differentiated treatment profile by combining rapid symptom relief, durable disease control, favorable safety, and convenient dosing in a single bispecific antibody therapy.
Advertisement
Phase 2b Development Planned Following Encouraging Early Results
Based on the positive proof-of-concept findings, Bambusa Therapeutics plans to rapidly advance BBT001 into a Phase 2b clinical trial evaluating dosing intervals of up to once every three months in patients with moderate-to-severe atopic dermatitis. The company is also conducting additional Phase 1 and Phase 2a studies in atopic dermatitis and chronic spontaneous urticaria (CSU) using both intravenous and subcutaneous formulations. Additional topline data from these ongoing studies are expected in the first half of 2027, providing further guidance for dose selection and future registrational development. With its dual-target approach against IL-4Rα and IL-31, BBT001 has the potential to establish a new treatment paradigm for Type 2 inflammatory diseases, offering patients faster, deeper, and longer-lasting disease control than currently available therapies.
Source: Bambusa Therapeutics press release
